The pharmacokinetics of vancomycin were characterized in 56 patients with different degrees of renal function after an intravenous dose of 18.4 + 4.7 mg kg-' (mean ± standard deviation). Seven subjects had a creatinine clearance (CLCR) of >60 ml min-' (group I), 13 had a CLCR of 10 to 60 ml min-1 (group II), and 36 had a CLCR of <10 ml min-l (group III Soc. Nephrol., 45A, 1980). However, only limited information is available regarding the pharmacokinetics of vancomycin in patients with mild to moderate renal insufficiency (6, 8, 10) . This study was designed to assess the relationship between renal function and vancomycin pharmacokinetics and develop a nomogram for vancomycin dosage in patients with various degrees of renal function.
The pharmacokinetics of vancomycin have been extensively evaluated in patients with end-stage renal disease (2, 3, 5, 7; F. Y. Lam, A. Lidner, J. Plorde, A. Blair, and R. E. Cutler, Abstr. Am. Soc. Nephrol., 45A, 1980) . However, only limited information is available regarding the pharmacokinetics of vancomycin in patients with mild to moderate renal insufficiency (6, 8, 10) . This study was designed to assess the relationship between renal function and vancomycin pharmacokinetics and develop a nomogram for vancomycin dosage in patients with various degrees of renal function.
MATERIALS AND METHODS
Patients. Fifty-six patients (27 males, 29 females) ranging in age from 17 to 85 years were studied. None of the patients had known hypersensitivity to vancomycin, and all patients had been started on vancomycin by their attending physicians for treatment of serious systemic infections. Patients were retrospectively divided into three groups on the basis of their calculated creatinine clearances (CLcRS), which were determined by the method of Cockroft and Gault (1).
Groups I, II, and III had CLCRS of >60, 10 to 60, and <10 ml min-, respectively. Of the 36 group III patients, 34 received chronic hemodialysis therapy.
The initial doses of vancomycin prescribed by the attending physicians ranged from 8.8 to 30.0 mg kg of body weight-' (18.4 ± 4.7 mg kg-1 [mean ± strandard deviation]) and were infused over a minimum period of 1 h. The kinetic study described below was carried out after the initial dose of vancomycin in ca. 70% of the patients, providing data utilized to assess further dosing requirements. Kinetic studies were done twice in 10 patients, three times in 3 patients, and four times in 1 patient. * Corresponding author.
Serial blood samples (range, 3 to 8) were obtained from a forearm vein in the arm opposite to that used for drug administration during the 24 h (group I), 96 h (group II), and 168 h (group III) after infusion. The sampling times were 3, 6, 9, 12, 24, 48, 72, 96, 120, 144, and 168 h after infusion. Collection times for individuals could vary from the described pattern. A preinfusion sample was obtained from patients who had received a prior dose of vancomycin. The initial postinfusion blood sample was drawn at least 3 h after the end of the intravenous infusion. Blood samples were allowed to clot; serum was separated by centrifugation and, if not immediately assayed for vancomycin, stored at -20°C. Previous studies have shown no loss of vancomycin activity in samples stored under these conditions for more than 1 year (6) .
Vancomycin concentrations in serum were determined in duplicate by radioimmunoassay (American Diagnostics, Newport Beach, Calif.). The minimum quantifiable vancomycin concentration was 1 mg liter-'. The interassay coefficients of variation for this procedure were 9, 6.5, and 9.8% at 4, 17, and 32 mg liter-1, respectively.
The postinfusion log vancomycin concentration in serumtime profiles were analyzed by the linear least-squares regression technique to estimate the elimination rate constant (k) and the serum concentration (Cmax) at the end of the infusion period. The elimination half-life (tl/2p), volume of distribution (V), and total body clearance (CLs) were calculated as t1/20 = 0.693/k, V = ko (1 - e-kt)Ik (Cmax -C0 e-kt), and CLs = k x V, respectively, where Co is the preinfusion concentration, ko is the infusion rate (milligrams per hour), and t is the infusion duration (hours).
The t1/2P, V, k, and CLs of the three groups were compared by analysis of variance. Differences between groups were subsequently analyzed by the unpaired Student t test.
The relationship between CLCR and t1/2P, V, k, and CLs were assessed by orthogonal regression analysis. The 0.05 level was chosen as the level of statistical significance. Tables 1, 2 , and 3, respectively. The profile of vancomycin CLCR ( Fig. 2 and 3 ). However, no significant relationship concentration in serum over time in all patients demonstratwas observed between V and CLCRed monoexponential decay (Fig. 1) The tj/20, CLs, and V of vancomycin in patients with CLCR, orthogonal regression analysis was used to obtain CLCRS of <10 ml min-' are similar to those in previous the kinetic parameters of vancomycin within a defined range of renal function, the relationship between vancomycin clearance and CLCR is highly significant. Declining renal function was associated with a marked reduction in the elimination of vancomycin, and dosage adjustment will therefore be required. Marked variability exists in the dosage recommendations which have been proposed for vancomycin. Doses have ranged form 13 to 32 mg kg-' day-' (10) in subjects with normal renal function and from 15 mg kg-1 after each hemodialysis (11) to 500 mg every 8 days (2) in patients with end-stage renal disease. The variability in these recommendations may be related to the relatively small number of patients evaluated by each inves- To use the nomogram, one must ascertain the CLCR of the patient. If CLCR cannot be measured directly, it should be estimated by using the patient age, body weight, and serum creatinine (1) . The interval (Xr) at which to administer the maintenance dose of 19 mg of vancomycin kg-' is then determined by passing a line perpendicular to the CLCR of the patient to the point at which it intercepts the sloping line of the nomogram. At the point of intercept, a horizontal line is drawn, intersecting the appropriate dosage interval on the right side of the nomogram. The dosing interval is given in fractions of days.
The nomogram may be utilized to aid in the initiation of vancomycin therapy for functionally anephric patients on hemodialysis, but not for patients treated with intermittent or continuous ambulatory peritoneal dialysis. Although intermittent peritoneal dialysis (9) and continuous ambulatory peritoneal dialysis therapy (Blevins et al., submitted for publication) may markedly alter the vancomycin dosing requirements of a patient, hemodialysis therapy has not been reported to require dosage adjustment (4, 5) . Adjustments in subsequent maintenance doses and the dosing interval should be guided by serial determinations of vancomycin concentrations in serum when they are available.
